OakChart

Syndax Pharmaceuticals Inc

SNDXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

9.59+0.10 (1.05%)
2026-11-12 04:31 CET
Market cap
863.37 USD m
Revenue, TTM
289.68 USD m
Net income, TTM
-209.48 USD m
Free cash flow, TTM
-177.46 USD m
EPS diluted, TTM
-2.37
P/E
-
Compare

Price

SNDX against its 20, 50 and 200-day averages
2050200miss
10.0015.0020.0025.007.5M15.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SNDXclose 9.5920-day 12.3750-day 15.72200-day 19.839.5952w high

62.5% under the 52-week high of 25.59 on 25 Mar 2026. 52-week low 9.15 on 9 Nov 2026. Last 15 sessions, 60.6% high to low

Volume 1.84× normal · the line is the 50-bar volume average

Profile

SNDX
52-week range, 3% of the way up
9.1525.59

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

IndexRUT
Employees298
IPOMar 03, 2016
Beta0.50
ATR, 14d0.96
Rel volume1.84
Short float23.12%
Insider own9.12%
Inst own112.78%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap863.37M
Enterprise Value1.03B
Income-209.48M
Sales289.68M
Book/sh-0.19
Cash/sh4.74
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees298
IPOMar 03, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S2.98
P/B-
P/C2.02
P/FCF-
EV/EBITDA-
EV/Sales3.54
Quick Ratio4.37
Current Ratio4.69
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.37
EPS next Y-0.98
EPS next Q-0.52
EPS this Y34.69%
EPS next Y54.24%
EPS next 5Y-
EPS past 3/5Y-10.26% -12.05%
Sales past 3/5Y- 157.68%
EPS Y/Y TTM34.52%
Sales Y/Y TTM159.68%
EPS Q/Q21.46%
Sales Q/Q81.59%
EarningsNov 02 AMC
EPS/Sales Surpr.-9.11% 2.36%

Ownership

Insider Own9.12%
Insider Trans-1.37%
Inst Own112.78%
Inst Trans7.72%
ROA-33.67%
ROE-426.43%
ROIC-36.64%
Gross Margin92.21%
Oper. Margin-61.67%
Profit Margin-72.32%
SMA20-22.48%
SMA50-39.01%
SMA200-51.65%
Trades-

Technical

Shs Outstand89.99M
Shs Float81.82M
Short Float23.12%
Short Ratio7.98
Short Interest18.92M
52W High25.59 -62.52%
52W Low9.15 4.87%
Volatility7.37% 7.78%
ATR (14)0.96
RSI (14)26.74
Beta0.50
Rel Volume1.84
Avg Volume2.37M
Volume4,355,627

Performance

Perf Week-8.23%
Perf Month-31.25%
Perf Quarter-49.74%
Perf Half Y-54.09%
Perf YTD-54.36%
Perf Year-45.91%
Perf 3Y-29.23%
Perf 5Y-45.60%
Perf 10Y-8.14%
Recom1.09
Target Price35.90
Prev Close9.49
Price9.59
Change %1.05%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2025ResumedHH.C. WainwrightBuy$40+317.1%
Sep 10, 2025ResumedSStifelBuy$44+358.8%
Sep 04, 2025ResumedGGuggenheimBuy$34+254.5%
Aug 05, 2025ReiteratedBBTIG ResearchBuy$43 → $56+483.9%
Jul 10, 2025InitiatedGGoldmanBuy$18+87.7%
Oct 24, 2024InitiatedUUBSBuy$37+285.8%
Jun 28, 2024InitiatedJJefferiesBuy$37+285.8%
Jan 31, 2024DowngradeBScotiabankSector Outperform → Sector Perform$36 → $23+139.8%
Dec 22, 2023InitiatedMMizuhoBuy$45+369.2%
Oct 25, 2023InitiatedBBofA SecuritiesBuy$29+202.4%

Peers

Mkt cap
TickerCompanyMkt cap
KURAKura Oncology Inc687.66M
INCYIncyte Corp24.92B
RIGLRigel Pharmaceuticals838.31M
AAPGAscentage Pharma Group International ADR1.40B
DMRADamora Therapeutics Inc1.44B
GERNGeron Corp657.13M
BMEABiomea Fusion Inc44.28M
TNGXTango Therapeutics Inc4.36B
CGONCg Oncology Inc6.49B
JNJJohnson & Johnson675.03B

Insider trading

latest 14 of 24
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Podlesak DennisDirectorOct 29 '26Option Exercise11.818,00094,480247,763Oct 30 07:09 PM
Podlesak DennisDirectorOct 29 '26Sale14.218,000113,716239,763Oct 30 07:09 PM
DENNIS G PODLESAKDirectorOct 29 '26Proposed Sale14.328,000114,560Oct 29 04:20 PM
Metzger Michael AChief Executive OfficerJul 08 '26Option Exercise6.3832,375206,552517,218Jul 09 04:54 PM
Metzger Michael AChief Executive OfficerJul 08 '26Sale24.2432,375784,776484,843Jul 09 04:54 PM
MICHAEL METZGERDirectorJul 08 '26Proposed Sale23.2432,375752,395Jul 08 04:39 PM
Botwood Nicholas A.J.Head of R&D, CMOJun 12 '26Option Exercise13.8231,235431,66892,120Jun 12 05:09 PM
Botwood Nicholas A.J.Head of R&D, CMOJun 11 '26Option Exercise13.8222,515311,15795,165Jun 12 05:09 PM
Botwood Nicholas A.J.Head of R&D, CMOJun 11 '26Sale18.0034,280617,04060,885Jun 12 05:09 PM
Botwood Nicholas A.J.Head of R&D, CMOJun 12 '26Sale18.1431,235566,60360,885Jun 12 05:09 PM
Botwood Nicholas A.J.OfficerJun 12 '26Proposed Sale18.1431,235566,693Jun 12 04:10 PM
Botwood Nicholas A.J.OfficerJun 11 '26Proposed Sale17.7834,280609,435Jun 11 04:12 PM
Goldan Keith A.Chief Financial OfficerJun 01 '26Sale18.991,17722,351139,252Jun 02 04:30 PM
Metzger Michael AChief Executive OfficerJun 01 '26Sale18.996,847130,025484,843Jun 02 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B

News

latest 14 of 200
  • Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
  • Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -26.87% -10.33%
  • Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026 (GlobeNewswire)
  • Syndax Highlights Acceptance of 19 Revuforj (revumenib) and Niktimvo (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026 (GlobeNewswire)
  • Syndax: Q3 Earnings Snapshot (Associated Press) +9.08%
  • Syndax Misses On EPS But Revuforj Rebound And Higher Niktimvo Margin Guide Sharpen The Commercial Story As Pipeline Setbacks Hang Over The Stock (Earnings Whispers)
  • Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Syndax Announces CFO Transition - Aaron A. Ondrey Appointed Chief Financial Officer (GlobeNewswire)
  • Syndax's Revuforj (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases (GlobeNewswire)
  • Syndax Announces Participation in November Investor Conferences (GlobeNewswire)
  • Syndax Must Show Revuforge's New-Patient Slump Was A Blip, Not A Trend (Earnings Whispers)
  • Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 (GlobeNewswire)
  • Syndax's Revuforj (revumenib) Named to TIME's Best Inventions of 2026 List (GlobeNewswire) -5.49%
  • J&J earnings set negative tone; Shkreli vs. the FTC (BioPharma Dive)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-02-0.550-0.504-0.55083.3081.3810
2026Q22026-08-04-0.550-0.448-0.55572.7979.3711
2026Q12026-04-30-0.480-0.608-0.48464.8669.7612
2025Q42026-02-26-0.780-0.584-0.77968.7364.3012
2025Q32025-11-03-0.700-0.725-0.70145.8748.0313
2025Q22025-08-04-0.830-1.016-0.83237.9626.8012
2025Q12025-05-05-0.980-1.252-0.98520.0416.4712
2024Q42025-03-03-1.100-0.839-1.0987.6835.1012
2024Q32024-11-05-0.980-1.070-0.98512.509.3213
2024Q22024-08-01-0.800-0.911-0.7983.500.0012
2024Q12024-05-08-0.850-0.979-0.8500.000.0011
2023Q42024-02-27-1.000-0.968-0.9990.000.0011
2023Q32023-11-02-0.730-0.785-0.7320.000.0011
2023Q22023-08-03-0.640-0.723-0.6410.000.009
2023Q12023-05-08-0.590-0.596-0.5920.000.607
2022Q42023-02-28-0.620-0.648-0.6200.001.338

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.840-1.825-1.8381.521.50
2020FY-1.870-1.864-1.8661.521.47
2021FY0.480-2.0420.465139.7119.15
2022FY-2.460-2.532-2.4580.000.38
2023FY-2.980-2.945-2.9750.000.00
2024FY-3.720-3.476-3.72323.6848.27
2025FY-3.290-3.103-3.290172.35168.15
2026FY--2.149--313.5
2027FY--0.983--456.04
2028FY-0.140--631.92
2029FY-1.466--864.36
2030FY-2.352--1,069

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-03101495.1087.27127.88
2026Q4S2026-11-02100395.7386.90128.49
2026Q4S2026-10-30110396.0386.90128.49
2026Q4S2026-10-28110395.9786.90127.89
2026Q4S2026-10-27110495.9786.90127.89
2026Q4S2026-10-24110495.9386.90127.89
2026Q4S2026-10-19110595.9386.90127.89
2026Q4S2026-10-121111095.9386.90127.89
2026Q4S2026-09-301111096.2486.90127.89
2026Q4S2026-09-071111097.0586.90127.89
2026Q4S2026-08-201111097.0586.90127.89
2026Q4S2026-08-14111998.6086.90127.89
2026Q4S2026-08-101119100.2186.90127.89
2026Q4S2026-08-051118102.3186.90127.89

Estimate history

EPS, annual-2.9-2.915-1.838-1.8660.465-2.458-2.975-3.723-3.295-2.3673
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.985-1.098-0.985-0.832-0.701-0.779-0.484-0.555-0.551
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.1081.5171.5171.517139.7090023.68172.352289.68
Period201720182019202020212022202320242025TTM
Sales, quarterly12.57.6820.04237.95845.87168.72864.86472.78883.298
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual24.3924.83627.1447.88154.98368.11184.82785.69487.40689.989
Period201720182019202020212022202320242025MRQ
Shares, quarterly85.57185.69486.04786.05986.90587.40688.54489.15189.989
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue289.68172.3523.680.000.00139.711.521.521.52
Cost of Goods Sold Incl. D&A22.566.980.830.010.450.46---
Gross Profit267.12165.3822.85-0.01-0.45139.25---
Selling, General and Administrative Excl. Other445.76438.46362.52229.94151.30113.0372.4258.6077.31
Research and Development272.99258.78241.64163.02118.0587.7950.4442.9960.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-178.64-273.08-339.67-229.95-151.7626.22-71.42-57.54-75.88
Interest Expense47.0933.784.930.213.141.902.360.000.00
Unusual Expense0.000.000.000.00-0.190.000.00--
Net Income Before Taxes-209.48-285.42-318.76-209.36-149.3424.93-73.16-56.05-73.96
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-209.48-285.42-318.76-209.36-149.3424.93-77.06-56.05-73.96
Net Income From Continuing Operations-209.48-285.42-318.76-209.36-149.3424.93-77.06-56.05-73.96
Net Income-209.48-285.42-318.76-209.36-149.3424.93-77.06-56.05-73.96
EPS (Recurring)-2.33-3.29-3.72-2.98-2.460.46-1.87-1.84-2.92
EPS (Basic, Before Extraordinaries)-2.37-3.29-3.72-2.98-2.460.48-1.87-1.84-2.92
EPS (Diluted)-2.37-3.29-3.72-2.98-2.460.46-1.87-1.84-2.92
EBITDA-178.62-273.08-339.66-229.94-151.3026.68-70.91-57.09-75.80
Non-Operating Income (Expense)16.2521.4525.8420.805.370.600.621.491.92
Other After Tax Adjustments0.000.000.000.000.000.00-3.910.000.00
Stock Option Compensation Expense52.6147.5043.0330.9512.6613.329.066.006.20
Price To Earnings Ratio----4,712.9647.16---
Price To Sales Ratio5.8310.5647.80--8.40605.60176.4774.43
Gross Margin92.2195.9596.48--99.67---
Operating Margin-61.67-158.45-1,434.43--18.77-4,708.17-3,792.95-5,001.71
Net Margin-72.32-165.60-1,346.11--17.84-5,080.03-3,694.59-4,875.48
Shares Outstanding89.9987.4185.6984.8368.1154.9847.8827.1424.84
Market Capitalization863.37863.371,128.431,738.501,706.211,150.301,029.80238.29110.52

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue83.3072.7964.8668.7345.8737.9620.047.68
Cost of Goods Sold Incl. D&A14.003.212.642.712.101.280.890.83
Gross Profit69.3069.5862.2366.0243.7736.6819.166.85
Selling, General and Administrative Excl. Other111.19109.5796.43128.57101.19106.03102.67103.22
Research and Development67.4768.0358.8478.6456.2862.2361.6465.53
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-41.90-39.99-34.20-62.55-57.43-69.35-83.51-96.36
Interest Expense12.9812.6811.859.598.287.868.054.81
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-49.43-49.36-42.67-68.01-60.72-71.85-84.85-94.17
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-49.43-49.36-42.67-68.01-60.72-71.85-84.85-94.17
Net Income From Continuing Operations-49.43-49.36-42.67-68.01-60.72-71.85-84.85-94.17
Net Income-49.43-49.36-42.67-68.01-60.72-71.85-84.85-94.17
EPS (Recurring)-0.55-0.55-0.48-0.78-0.70-0.83-0.98-1.10
EPS (Basic, Before Extraordinaries)-0.55-0.55-0.48-0.78-0.70-0.83-0.98-1.10
EPS (Diluted)-0.55-0.55-0.48-0.78-0.70-0.83-0.98-1.10
EBITDA-41.89-39.99-34.20-62.55-57.42-69.35-83.51-96.36
Non-Operating Income (Expense)5.443.313.384.134.995.366.717.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.2914.0112.0511.2512.0813.7910.3812.30
Price To Sales Ratio5.837.719.4810.6311.9510.3424.2147.90
Gross Margin83.1995.5995.9396.0695.4296.6395.5889.24
Operating Margin-50.30-54.95-52.73-91.01-125.19-182.71-416.67-1,254.75
Net Margin-59.34-67.82-65.79-98.96-132.36-189.28-423.34-1,226.16
Shares Outstanding89.9989.1588.5487.4186.9186.0686.0585.69
Market Capitalization863.371,937.012,060.371,826.081,325.29805.831,056.811,128.43

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments394.07572.88570.70475.80440.05293.1859.7781.01130.08
Short Term Receivables70.2913.871.234.060.430.170.120.250.38
Inventories32.750.370.000.000.000.000.000.000.00
Other Current Assets30.9715.948.959.937.925.512.442.082.98
Total Current Assets528.08603.06580.88489.79448.40298.8662.3383.35133.44
Net Property, Plant & Equipment1.522.021.501.061.260.481.000.370.27
Total Investments and Advances0.10119.7430.055.580.000.120.120.003.25
Intangible Assets0.000.00--0.00----
Other Assets0.000.000.460.810.001.150.080.220.23
Total Assets529.71724.82612.88497.24449.66300.6163.5283.94137.19
Short Term Debt Incl. Current Port. of LT Debt0.4712.601.050.440.362.600.480.000.00
Accounts Payable16.5811.639.964.355.673.516.181.442.23
Other Current Liabilities103.0679.3347.0924.2814.6512.7611.7114.6713.57
Total Current Liabilities120.12103.5558.1029.0720.6818.8718.3716.1115.80
Long Term Debt344.96333.140.590.7220.6117.930.420.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.0011.6213.1414.7917.07
Total Liabilities465.08436.6958.6829.7941.2948.4231.9330.8932.87
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity64.63288.12554.20467.45408.37252.1931.6053.05104.32
Total Shareholders Equity64.63288.12554.20467.45408.37252.1931.6053.05104.32
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity64.63288.12554.20467.45408.37252.1931.6053.05104.32
Total Liabilities & Stockholders Equity529.71724.82612.88497.24449.66300.6163.5283.94137.19
Book Value Per Share0.743.366.536.867.435.271.162.144.28
Tangible Book Value Per Share0.743.366.536.867.435.271.162.144.28
Full-Time Employees2982701841075943353845
Price to Book Ratio-50.233.094.194.532.954.227.542.082.02
Return on Assets-45.50-47.66-37.72-31.546.64-42.33-76.02-66.90-49.39
Return on Equity-161.82-75.69-40.98-34.107.55-54.31-132.43-94.00-64.53
Return on Invested Capital-69.68-51.31-37.74-31.905.81-28.53-175.04-139.43-58.28
Quick Ratio4.125.8210.0016.8521.6815.843.395.188.45
Current Ratio4.405.8210.0016.8521.6815.843.395.188.45

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-209.48-285.42-318.76-209.36-149.3424.93-73.16-56.05-73.96
Depreciation0.020.010.010.010.450.460.520.450.08
Other Funds (Non Cash)51.1241.7530.5816.8913.5513.359.325.225.65
Funds from Operations-158.35-243.66-288.17-192.46-135.3338.73-63.33-50.37-68.23
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-19.01-79.3213.2731.861.66-9.60-7.93-0.24-0.30
Cash from Operating Activities-177.36-322.98-274.90-160.60-133.6829.13-71.26-50.61-68.53
Capital Expenditures-0.10-0.190.000.000.00-0.130.000.00-0.19
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.230.000.000.00-
Purchase or Sale of Investments-73.32290.22-219.78117.61-186.41-40.74-142.5312.7851.59
Purchase of Investments-427.00-195.81-557.05-354.61-495.35-294.72-278.94-104.02-78.84
Sale Or Maturity of Investments353.68486.03337.28472.21308.93253.97136.41116.80130.43
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-73.42290.04-219.78117.61-186.19-40.87-142.5312.7851.40
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock25.9613.689.71264.13193.25118.46284.6928.5715.72
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock25.9613.689.71264.13193.25118.46284.6928.5715.72
Proceedsfrom Stock Options0.000.000.000.00181.39111.76277.7128.2115.50
Issuance or Reduction of Debt, Net243.840.000.000.00-21.000.0019.730.000.00
Change in Long Term Debt243.840.000.000.00-21.000.0019.730.000.00
Issuance of Long Term Debt250.000.000.000.000.000.0019.730.000.00
Reduction of Long Term Debt-6.170.000.000.00-21.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00343.650.000.000.000.000.000.01
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities269.7913.68353.37264.13172.25118.46304.4228.5715.73
Net Change in Cash19.02-19.27-141.31221.14-147.61106.7290.63-9.26-1.40
Free Cash Flow-177.46-323.17-274.90-160.60-133.6829.00-71.26-50.61-68.72
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-----40.47---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments427.10547.86352.06394.07435.98455.23
Short Term Receivables79.7872.7860.6970.2943.0637.42
Inventories39.3833.1634.9532.7525.0017.70
Other Current Assets21.1721.2323.4730.9725.7921.32
Total Current Assets567.44675.04471.18528.08529.83531.68
Net Property, Plant & Equipment1.161.291.391.521.601.63
Total Investments and Advances124.0827.320.100.1020.3662.84
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets692.67703.65472.67529.71551.79596.15
Short Term Debt Incl. Current Port. of LT Debt0.530.510.490.4723.2619.79
Accounts Payable3.574.8710.8416.5813.8317.35
Other Current Liabilities116.8694.3074.84103.0677.1175.85
Total Current Liabilities120.9699.6886.17120.12114.19112.99
Long Term Debt588.89588.88344.87344.96322.18325.74
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities709.85688.55431.05465.08436.36438.73
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-17.1815.1041.6264.63115.43157.42
Total Shareholders Equity-17.1815.1041.6264.63115.43157.42
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-17.1815.1041.6264.63115.43157.42
Total Liabilities & Stockholders Equity692.67703.65472.67529.71551.79596.15
Book Value Per Share-0.190.170.470.741.331.83
Tangible Book Value Per Share-0.190.170.470.741.331.83
Full-Time Employees---298--
Price to Book Ratio-50.2346.5031.5915.828.413.75
Return on Assets-33.67-33.97-43.70-45.50-63.74-62.43
Return on Equity-426.43-255.93-189.53-161.82-129.32-113.22
Return on Invested Capital-8.65-8.17-11.04-16.61-13.87-14.87
Quick Ratio4.376.445.064.124.424.55
Current Ratio4.696.775.474.404.644.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-49.43-49.36-42.67-68.01-60.72-71.85
Depreciation0.010.010.000.000.000.00
Other Funds (Non Cash)15.1614.2911.3810.2813.5610.80
Funds from Operations-34.26-35.06-31.29-57.73-47.16-61.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital7.014.79-19.05-11.76-23.38-26.75
Cash from Operating Activities-27.25-30.27-50.34-69.49-70.53-87.80
Capital Expenditures0.00-0.040.00-0.06-0.130.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-176.47-16.8738.3981.6372.5641.89
Purchase of Investments-238.63-85.87-39.39-63.12-30.44-91.71
Sale Or Maturity of Investments62.1669.0077.78144.75103.00133.60
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-176.47-16.9138.3981.5872.4341.89
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.208.927.925.926.280.55
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.208.927.925.926.280.55
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.01243.850.000.000.000.00
Change in Long Term Debt-0.01243.850.000.000.000.00
Issuance of Long Term Debt0.00250.000.000.000.000.00
Reduction of Long Term Debt-0.01-6.150.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.19252.777.925.926.280.55
Net Change in Cash-200.54205.58-4.0418.018.17-45.36
Free Cash Flow-27.25-30.31-50.34-69.54-70.67-87.80

Revenue breakdown

Collaboration revenue2025: 42.37M
Milestone2024: 16.00M 2025: 5.14M
Net Product Revenues2024: 7.68M 2025: 124.84M
United States2024: 23.68M 2025: 172.35M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3023.12%18.9M81.8M1.95M
2026-10-1522.18%18.0M81.2M1.65M
2026-09-3022.47%18.2M81.2M1.61M
2026-09-1525.46%20.7M81.2M1.66M
2026-08-3126.74%21.7M81.1M1.79M
2026-08-1428.29%22.9M81.0M1.80M
2026-07-3127.85%22.7M81.4M1.89M
2026-07-1525.78%20.8M80.8M1.96M
2026-06-3027.01%21.8M80.8M1.85M
2026-06-1524.70%19.9M80.4M1.66M
2026-05-2920.62%16.6M80.7M1.55M
2026-05-1527.00%21.7M80.4M1.57M
2026-04-3023.37%19.9M85.2M1.42M
2026-04-1524.73%21.0M84.8M1.37M
2026-03-3124.42%20.7M84.8M1.37M
2026-03-1324.17%20.5M84.8M1.32M
2026-02-2725.72%21.8M84.8M1.37M
2026-02-1326.49%22.1M83.5M1.57M
2026-01-3025.09%21.1M84.3M1.94M
2026-01-1526.51%22.3M84.3M2.48M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.006.7010.6013.250.0003.000.000.992-0.0150.000
call2.005.709.607.5631.1262.000.000.987-0.0160.000
call3.004.708.606.7016.6091.001.000.983-0.0160.001
call4.003.707.600.0012.2920.000.000.977-0.0150.001
call5.002.656.604.719.7161.000.000.970-0.0150.001
call6.001.705.600.007.8600.000.000.960-0.0140.001
call7.000.704.700.006.6240.000.000.946-0.0130.002
call8.000.053.700.005.3510.000.000.920-0.0120.002
call9.000.002.800.004.4030.000.000.644-0.0580.006
call10.000.000.350.250.86748.0010.000.425-0.0330.006
call11.000.001.000.100.8321961680.162-0.0170.004
call12.000.000.150.051.15914835.000.126-0.0200.003
call13.000.002.100.201.4361020.000.107-0.0220.003
call14.000.000.500.011.6801200.000.095-0.0240.003
call15.000.000.500.251.89786.000.000.086-0.0250.002
call16.000.002.150.282.09445.000.000.080-0.0260.002
call17.000.002.150.412.2742720.000.075-0.0270.002
call18.000.002.150.252.44047.000.000.071-0.0280.002
call19.000.001.200.092.2881130.000.041-0.0170.001
call20.000.002.150.192.4214110.000.039-0.0170.001
call21.000.002.150.102.5461040.000.038-0.0180.001
call22.000.002.150.112.6631,0350.000.036-0.0180.001
call23.000.002.151.152.77413.000.000.035-0.0180.001
call24.000.002.150.952.8804170.000.034-0.0180.001
call25.000.000.250.202.9792,6560.000.033-0.0190.001
call26.000.001.401.203.0754.000.000.033-0.0190.001
call27.000.002.150.003.1650.000.000.032-0.0190.001
call28.000.000.202.263.2521030.000.031-0.0190.001
call29.000.002.152.553.3351.000.000.031-0.0200.001
call30.000.000.150.853.41554.000.000.030-0.0200.001
call31.000.002.150.003.4920.000.000.030-0.0200.001
call32.000.002.150.003.5650.000.000.029-0.0200.001
call33.000.002.151.803.6366.000.000.029-0.0200.001
call35.000.002.150.003.7240.000.000.028-0.0200.001
put1.000.002.150.008.1640.000.00-0.008-0.0150.000
put2.000.002.150.005.5880.000.00-0.013-0.0150.000
put3.000.002.150.004.1930.000.00-0.017-0.0150.001
put4.000.002.150.003.2290.000.00-0.023-0.0150.001
put5.000.002.150.002.4870.000.00-0.030-0.0140.001
put6.000.002.150.121.8781.000.00-0.040-0.0140.001
put7.000.000.100.001.9980.000.00-0.136-0.0340.003
put8.000.000.050.151.4180.005.00-0.158-0.0290.004
put9.000.000.450.351.2331270.00-0.356-0.0570.006
put10.000.401.000.501.29282.000.00-0.575-0.0320.006
put11.000.402.601.552.8712400.00-0.838-0.0160.004
put12.001.053.402.602.98670.000.00-0.874-0.0190.003
put13.002.904.503.903.5441680.00-0.893-0.0210.003
put14.002.456.300.605.2500.000.00-0.905-0.0220.003
put15.003.407.303.005.55775.000.00-0.914-0.0240.002
put16.004.408.305.705.83313.000.00-0.920-0.0250.002
put17.005.409.308.506.0843.000.00-0.925-0.0250.002
put18.006.4010.304.006.3140.000.00-0.929-0.0260.002
put19.007.4011.305.656.5262.000.00-0.959-0.0150.001
put20.008.4012.306.206.7235.000.00-0.961-0.0150.001
put21.009.4013.300.006.9060.000.00-0.962-0.0150.001
put22.0010.4014.300.007.0780.000.00-0.964-0.0160.001
put23.0011.4015.300.007.2390.000.00-0.965-0.0160.001
put24.0012.4016.306.507.3920.000.00-0.966-0.0160.001
put25.0013.4017.300.007.5360.000.00-0.967-0.0160.001
put26.0014.4018.300.007.6720.000.00-0.967-0.0160.001
put27.0015.4019.300.007.8020.000.00-0.968-0.0160.001
put28.0016.4020.300.007.9260.000.00-0.969-0.0160.001
put29.0017.4021.300.008.0440.000.00-0.969-0.0160.001
put30.0018.4022.300.008.1570.000.00-0.970-0.0160.001
put31.0019.4023.300.008.2660.000.00-0.970-0.0160.001
put32.0020.4024.300.008.3700.000.00-0.971-0.0160.001
put33.0021.4025.300.008.4700.000.00-0.971-0.0170.001
put35.0023.4027.3021.408.6590.000.00-0.972-0.0170.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-29144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13GSEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-148-KCurrent report2026-07-14SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-08144Filing for proposed sale of securities under Rule 144.SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-11144Filing for proposed sale of securities under Rule 144.SEC
2026-06-108-KCurrent report2026-06-10SEC
2026-06-108-KCurrent report2026-06-10SEC
2026-06-04DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-05-15SCHEDULE 13G/ASEC
2026-04-30SCHEDULE 13GSEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-04-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-308-KCurrent report2026-04-30SEC
2026-03-27SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000113.72K1
2026-090000
2026-080000
2026-0700784.78K1
2026-06001.34M4
2026-050000
2026-040000
2026-030000
2026-0200628.29K4
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.10.18%
Kynam Capital Management, LP9.09%
GOLDMAN SACHS GROUP INC6.61%
STATE STREET CORP6.39%
BANK OF AMERICA CORP /DE/4.57%
VANGUARD CAPITAL MANAGEMENT LLC4.43%
DEERFIELD MANAGEMENT COMPANY, L.P.4.27%
Eversept Partners, LP3.16%
Hood River Capital Management LLC2.89%
KINGDON CAPITAL MANAGEMENT, L.L.C.2.82%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.98%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.19%
iShares Russell 2000 ETF2.61%
Hood River Small-Cap Growth Fund1.37%
VANGUARD EXTENDED MARKET INDEX FUND1.14%
Fidelity Small Cap Index Fund1.10%
Franklin Small Cap Growth Fund1.05%
iShares Russell 2000 Growth ETF0.93%
Franklin Biotechnology Discovery Fund0.66%
iShares Biotechnology ETF0.65%

OakChart. SNDX. Cached 15 minutes.